ArticlePharmaceuticals (Basel, Switzerland)2026
A CXCR4/PD-L1 Bispecific Nanobody Engineered for Tumor Microenvironment Retention Mediates Sustained Synergy with Chemotherapy via Remodeling Immunity in TNBC.
Shuyi Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.